TY - JOUR
T1 - Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment
AU - Fu, Junzeng
AU - Cuppen, Bart V J
AU - Welsing, Paco M J
AU - van Wietmarschen, Herman
AU - Harms, Amy C.
AU - Berger, Ruud
AU - Koval, Slavik
AU - Fritsch-Stork, Ruth D E
AU - Bijlsma, Johannes W J
AU - Hankemeier, Thomas
AU - van der Greef, Jan
AU - Lafeber, Floris P J G
PY - 2016/12
Y1 - 2016/12
N2 - Objective: As there are pharmacological differences between males and females, and glucocorticoid (GC) treatment is associated with increased cardiovascular mortality rate in rheumatoid arthritis (RA) patients, it is important to study serum polar lipid profiles of male and female patients in response to GC therapy. Gender differences may require an adjustment to the treatment strategy for a selection of patients. Methods: Serum samples from 281 RA patients were analysed using a targeted lipidomics platform. The differences in GC use and gender on polar lipid profiles were cross sectionally examined by multiple linear regressions, while correcting for confounding factors. Results: Differences in polar lipids between GC users and non-GC users in females and males were merely restricted to lysophospholipids (lysophosphatidylcholines and lysophosphatidylethanolamines). Lysophospholipids in female patients treated with GCs were significantly higher than female patients not treated with GCs (p = 6.0 E−6), whereas no significant difference was observed in male GC users versus non-users (p = 0.397). Conclusion: The lysophospholipid profiles in response to GCs were significantly different between male and female RA patients, which may have implications for the cardiovascular risk of GC treatment.
AB - Objective: As there are pharmacological differences between males and females, and glucocorticoid (GC) treatment is associated with increased cardiovascular mortality rate in rheumatoid arthritis (RA) patients, it is important to study serum polar lipid profiles of male and female patients in response to GC therapy. Gender differences may require an adjustment to the treatment strategy for a selection of patients. Methods: Serum samples from 281 RA patients were analysed using a targeted lipidomics platform. The differences in GC use and gender on polar lipid profiles were cross sectionally examined by multiple linear regressions, while correcting for confounding factors. Results: Differences in polar lipids between GC users and non-GC users in females and males were merely restricted to lysophospholipids (lysophosphatidylcholines and lysophosphatidylethanolamines). Lysophospholipids in female patients treated with GCs were significantly higher than female patients not treated with GCs (p = 6.0 E−6), whereas no significant difference was observed in male GC users versus non-users (p = 0.397). Conclusion: The lysophospholipid profiles in response to GCs were significantly different between male and female RA patients, which may have implications for the cardiovascular risk of GC treatment.
KW - Gender difference
KW - Glucocorticoid
KW - Lysophospholipid
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84988966591&partnerID=8YFLogxK
U2 - 10.1007/s10787-016-0284-1
DO - 10.1007/s10787-016-0284-1
M3 - Article
C2 - 27682325
AN - SCOPUS:84988966591
SN - 0925-4692
VL - 24
SP - 397
EP - 402
JO - Inflammopharmacology
JF - Inflammopharmacology
IS - 6
ER -